CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM071624
035-os BibID:(Cikkazonosító)399 (WOS)000419673100035 (Scopus)85040450338
Első szerző:Tornai Tamás István (belgyógyász)
Cím:Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis / Tornai Tamas, Tornai David, Sipeki Nora, Tornai Istvan, Alsulaimani Rayan, Fechner Kai, Roggenbuck Dirk, Norman Gary L., Veres Gabor, Par Gabriella, Par Alajos, Szalay Ferenc, Lakatos Peter Laszlo, Antal-Szalmas Peter, Papp Maria
Dátum:2018
Megjegyzések:Glycoprotein 2[GP2] is a specific target of pancreatic autoantibodies[PAbs] in Crohn's disease(CD) and is involved in gut innate immunity processes. Our aim was to evaluate the prevalence and prognostic potential of PAbs in primary sclerosing cholangitis(PSC). Sixty-five PSC patients were tested for PAbs by indirect immunofluorescence and compared with healthy (n=100) and chronic liver disease controls(CLD, n=488). Additionally, a panel of anti-microbial antibodies and secretory (s)IgA levels were measured, as markers of bacterial translocation and immune dysregulation. PAbs were more frequent in PSC (46.2%) compared to controls(healthy:0% and CLD:4.5%), P<0.001, for each]. Occurrence of anti-GP2 antibody was 30.8% (20/65) and was exclusively of IgA isotype. Anti-GP2 IgA positive patients had higher sIgA levels (P=0.021). With flow-cytometry, 68.4% (13/19) of anti-GP2 IgA antibodies were bound with secretory component, suggesting an active retro-transportation of anti-GP2 from the gut lumen to the mucosa. Presence of anti-GP2 IgA was associated with shorter transplant-free survival [PLogRank<0.01] during the prospective follow-up (median, IQR: 87 [9-99] months) and remained an independent predictor after adjusting for Mayo risk score (HR: 4.69 [1.05-21.04], P=0.043). These results highlight the significance of gut-liver interactions in PSC. Anti-GP2 IgA might be a valuable tool for risk stratification in PSC and considered as a potential therapeutic target.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
primary sclerosing cholangitis
pancreatic autoantibodies
glycoprotein 2
CUZD1
secretory immunglobulin
gut failure
Megjelenés:Scientific Reports. - 8 : 1 (2018), p. 1-11. -
További szerzők:Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Sipeki Nóra (1987-) (általános orvos) Tornai István (1954-) (belgyógyász, gasztroenterológus) Alsulaimani, Rayan Fechner, Kai Roggenbuck, Dirk Norman, Gary L. Veres Gábor (orvos) Pár Gabriella Pár Alajos Szalay Ferenc (belgyógyász) Lakatos Péter (Semmelweis Egyetem) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:OTKA-115818
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1